"Physician Views: Can Portola's Reversal Agent Act as Growth Catalyst for Novel Anticoagulants?" Published
Initial Phase III data released by Portola Pharmaceuticals last week appears to have nudged its recombinant Factor Xa antidote andexanet alfa closer to market. The product is designed to be used in patients who have received therapy with a Factor Xa inhibitor, but whom subsequently need the anticoagulant action to be reversed due to bleeding or the requirement for surgery.
View full press release